ALEC vs PEPG
ALEC: An early-stage biotech company developing novel therapeutic candidates for neurodegenerative diseases through preclinical research and clinical trials. PEPG: PepGen is a biotechnology company developing novel oligonucleotide therapies that use proprietary peptide-based delivery technology to treat severe neuromuscular and neurological diseases.
Side-by-side fundamentals
| Metric | ALEC | PEPG | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $1.51 | $1.90 | |
| Market cap as of 2026-07-30 | $168M | $118M | |
| Net margin as of 2026-07-30 | -680.8% | n/a | |
| Operating margin as of 2026-07-30 | -739.7% | n/a | |
| ROE as of 2026-07-30 | -295.2% | -59.9% | PEPG higher |
| ROA as of 2026-07-30 | -40.9% | -49.6% | ALEC higher |
| Debt / equity as of 2026-07-30 | 0.94 | 0.00 | PEPG lower |
| Revenue growth (YoY) as of 2026-07-30 | -79.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -46.0% | n/a | |
| Beta as of 2026-07-30 | 0.59 | 1.86 | |
| 1-year return as of 2026-07-27 close | -14.2% | +31.0% | PEPG higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.